Surfactant Lipids, Compositions Thereof, and Uses Thereof
The invention generally relates to methods to inhibit inflammation or pathogen infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one anionic lipid or compositions comprising at least one anionic lipid to an individual. The invention further relates to compositions comprising randomly mixed surfactant lipids and methods to produce the compositions.
1 .- 36 . (canceled)
37 . A method to inhibit inflammation, comprising administering to an individual who has, or is at risk of developing said inflammation, a composition comprising at least one anionic lipid or related compound, wherein the anionic lipid or related compound is effective to inhibit said inflammation, and wherein the anionic lipid has the following characteristics:
a) has a hydrophobic portion;
b) has a negatively charged portion; and
c) has an uncharged, polar portion; and
wherein the composition is selected from the group consisting of:
i) a homogeneous lipid preparation consisting of the anionic lipid or related compound;
ii) a composition comprising a homogeneous lipid preparation of the anionic lipid or related compound and at least one agent for the treatment of inflammation;
iii) a composition comprising a preparation of randomly mixed surfactant lipids combined with a homogeneous lipid preparation of the anionic lipid or related compound; and
iv) a preparation of randomly mixed surfactant lipids, wherein the anionic lipid or related compound comprises at least about 50% of the total lipids in said randomly mixed surfactant lipids.
38 . The method of claim 37 , wherein the anionic lipid or related compound is selected from the group consisting of: phosphatidylglycerol, unsaturated phosphatidylglycerol, unsaturated phosphatidylinositol, saturated short chain phosphatidylglycerol, saturated short chain phosphatidylinositol, anionic sphingolipid, anionic glycerolipid, unsaturated lyso-phosphatidylglycerol, saturated lyso-phosphatidylglycerol, unsaturated lyso-phosphatidylinositol, and saturated lyso-phosphatidylinositol, or a derivative thereof.
39 . The method of claim 37 , wherein the anionic lipid is selected from the group consisting of: an unsaturated phosphatidylglycerol, an unsaturated phosphatidylinositol, a saturated short chain phosphatidylglycerol, and a saturated short chain phosphatidylinositol, or a derivative of the anionic lipid.
40 . The method of claim 37 , wherein the composition is a preparation of randomly mixed surfactant lipids combined with a homogeneous lipid preparation of the anionic lipid or related compound.
41 . The method of claim 37 , wherein the composition is a homogeneous lipid preparation of the anionic lipid or related compound and at least one additional agent for treating inflammation.
42 .- 73 . (canceled)
74 . The method of claim 37 , wherein the composition is administered to the respiratory tract of the individual.
75 . The method of claim 37 , wherein the composition is administered to the individual prior to any indication of inflammation.
76 . The method of claim 37 , wherein the composition is administered to individual subsequent to identification of a symptom of or confirmation of inflammation.
77 . The method of claim 37 , wherein the individual is a neonatal infant.